Your browser doesn't support javascript.
loading
Repurposed prophylaxis strategies for COVID-19: a systematic review
Erwan Sallard; Francois-Xavier Lescure; Charles Burdet; Jeremie Guedj; Yazdan Yazdanpanah; Nathan Peiffer-Smadja.
Affiliation
  • Erwan Sallard; Ecole Normale Superieure de Paris, 45 Rue D'Ulm, 75005, Paris, France
  • Francois-Xavier Lescure; Universite de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hopitaux de Paris, Bichat- Clau
  • Charles Burdet; Universite de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hopitaux de Paris, Bichat- Clau
  • Jeremie Guedj; Universite de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hopitaux de Paris, Bichat- Clau
  • Yazdan Yazdanpanah; Universite de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hopitaux de Paris, Bichat- Clau
  • Nathan Peiffer-Smadja; Universite de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hopitaux de Paris, Bichat- Clau
Preprint in En | PREPRINT-MEDRXIV | ID: ppmedrxiv-20117937
ABSTRACT
IntroductionEfficient therapeutic strategies are needed to counter the COVID-19 pandemic, caused by the SARSCoV-2 virus. In a context where specific vaccines are not yet available, the containment of the pandemic would be facilitated with efficient prophylaxis. MethodsWe screened several clinical trials repositories and platforms in search of the prophylactic strategies that are investigated against COVID-19 in late April 2020. ResultsUp to April 27, 2020, we found 68 clinical trials targeting medical workers (n = 43, 63%), patients relatives (n = 16, 24%) or individuals at risk of severe COVID-19 (n = 5, 7%). (Hydroxy)chloroquine was the most frequently evaluated treatment (n = 46, 68%), before BCG vaccine (n = 5, 7%). Sixty-one (90%) clinical trials were randomized with a median of planned inclusions of 600 (IQR 255-1515). ConclusionThe investigated prophylaxis strategies cover both pre- and post-exposure prophylaxis and study numerous immune enhancers and antivirals, although most research efforts are focused on (hydroxy)chloroquine.
License
cc_by_nd
Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Experimental_studies / Prognostic_studies / Rct / Review / Systematic_reviews Language: En Year: 2020 Document type: Preprint
Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Experimental_studies / Prognostic_studies / Rct / Review / Systematic_reviews Language: En Year: 2020 Document type: Preprint